GARP expressed on HSCs drives the development of liver fibrosis via cell contraction‐mediated activation of latent TGF‐β, suggesting GARP as a novel target for the treatment of fibrotic disease.160. This evidence concerns the gene LRRC32 and Hepatic fibrosis.